MOLECULAR INEQUALITY IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) AND IMPLICATIONS FOR CLINICAL TRIALS

被引：0
|
作者：
Naidoo, Jarushka [1 ]
Noonan, Sinead [2 ]
Teo, Min Yuen [3 ]
Rho, Young Soo [1 ]
Clince, Janet [1 ]
Gately, Kathy [4 ]
O'Grady, Tony [5 ]
Kaye, Elaine [5 ]
Calvert, Paula [6 ]
Morris, Patrick G. [7 ]
O'Brien, Cathal [4 ]
O'Byrne, Kenneth [8 ]
Breathnach, Oscar S. [1 ]
机构：
[1] Beaumont Hosp, Dublin, Ireland
[2] St James Hosp, Dublin, Ireland
[3] Inc Natl Childrens Hosp, Adelaide & Meath Hosp, Dublin 24, Ireland
[4] Univ Dublin Trinity Coll, Dublin 2, Ireland
[5] Beaumont Hosp, Dublin, Ireland
[6] Waterford Reg Hosp, Waterford, Ireland
[7] Hermitage Clin, Dublin, Ireland
[8] Princess Alexandra Hosp, Woolloongabba, Qld, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Treatment; non-small cell lung cancer; Cinical Trials; Inequality;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-042
引用
收藏
页码：S1208 / S1208
页数：1
相关论文
共 50 条
  • [21] IMPROVING TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Reck, M.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4038 - 4038
  • [22] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [23] Anthocyanins in Non-Small Cell Lung Cancer (NSCLC) Treatment and Prevention
    Papavassiliou, Kostas A.
    Sofianidi, Amalia A.
    Papavassiliou, Athanasios G.
    NUTRIENTS, 2024, 16 (10)
  • [24] Predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC)
    Niho, Seiji
    CANCER SCIENCE, 2018, 109 : 423 - 423
  • [25] Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)
    Kumarakulasinghe, Nesaretnam Barr
    van Zanwijk, Nico
    Soo, Ross A.
    RESPIROLOGY, 2015, 20 (03) : 370 - 378
  • [26] Neoadjuvant treatment in the clinical practice of locally advanced non-small cell lung cancer (NSCLC).
    Arcuri, C
    Caffo, O
    Vanoni, V
    Silvestri, M
    Valduga, F
    Santarossa, S
    Galligioni, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 702S - 702S
  • [27] IDENTIFYING ATMic NON-SMALL CELL LUNG CANCER CELL LINES: IMPLICATIONS FOR DESIGNING CLINICAL TRIALS
    Bebb, G.
    Elegbede, A.
    Petersen, L.
    Williamson, C.
    Lees-Miller, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 29 - 29
  • [28] Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).
    Park, Lee Chun
    Rhee, Kyunghoon
    Kim, Won Bin
    Cho, Anderson
    Song, Junho
    Anker, Jonathan Forrest
    Oh, Michael
    Bais, Preeti
    Namburi, Sandeep
    Chuang, Jeffrey
    Chae, Young Kwang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Cost implications of clinical trial (CT) participation in metastatic non-small cell lung cancer (NSCLC).
    Merkhofer, Cristina
    Chennupati, Shasank
    Sun, Qin
    Eaton, Keith D.
    Martins, Renato G.
    Ramsey, Scott David
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Molecular marker expression in non-small cell lung cancer (NSCLC) in Humberside
    Roejkjaer, Eline
    Saleem, Azeem
    LUNG CANCER, 2024, 190
12345